- News & Events
News & Events
Genix will now be called Qualicaps®
Sao Paulo, May 2018 – From May 02nd, Genix will be called Qualicaps®. Acquired at the end of 2015 by Qualicaps®, a wholly owned subsidiary of Mitsubishi Chemical Holdings Corporation, the Brazilian company has been in operating for 13 years. It is the national leader in the production of two-piece hard capsules for the pharmaceutical industry, as well as for nutraceutical products, and is recognized for the excellence of its international standards of technology. The Company is certified for Good Manufacturing Practices and Pharmaceutical Ingredients by ANVISA – the Brazilian Health Regulatory Agency.
In two years since the company has formed part of Qualicaps®, the subsidiary has grown by 18,7% in its operation and currently employs 340 people in the country. It is also the only supplier of hard capsules with a production center in Brazil, consolidating Qualicaps® as the leader in the country that is the eighth largest pharmaceutical market in the world.
“Changing the company’s name is part of a natural process, due to the recognition of our technological quality by our customers and regulators, by the growth in our operation and by the perspective of greater regional performance. Latin America is a strategic market for Qualicaps®, which was already developing partnerships in other regions and identified in Genix the real possibility of covering this market and becoming the number one supplier of the pharmaceutical industry,” says Paulo Valente, President for Latin America.
With more than a century of experience and a strong history of pioneering in new forms of drug administration, Qualicaps® is responsible for several milestones in the development of hard capsules, introducing features that have become standard in the industry, such as being the first to create formulas without preservatives for gelatin capsules, and to develop capsules from vegetable origin (HPMC) for the pharmaceutical market.
In addition to the Brazilian factory, Qualicaps® has a global presence with manufacturing units in Japan, Spain, Romania, Canada, and the United States. The Brazilian subsidiary is responsible for serving the pharmaceutical and consumer healthcare markets in Latin America. Only in Brazil, the pharmaceutical market is expected to grow about 3.5% between 2018 and 2021, registering nearly US$ 30 billion in 2021, according to Global Health Intelligence.
- Engineered to perform
12th PBP World Meeting 2021 – MAY 11-14, 2021
The 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP World Meeting) will be held this year as an online conference due to the current world pandemic situation. This meeting is intended to bring together people working in fundamental and applied academic research, chemical and pharmaceutical industry, and the regulatory field, offering the opportunity to initiate fruitful discussions and collaborations.
During this 3-day conference among others, some posters, where Qualicaps® has worked closely with their presenters in the studies leading to them, will be divulged, such as the poster “Comparing the mechanical properties of Quali-V®-I and Quali-V®-I Extra Dry Capsules for use in Dry Powder Inhalers” (to be exposed by the University of Cardiff) and also, the study “How important is internal lubricant in capsules for inhalation?” (to be presented by the RCPE Consortium).
Respiratory Drug Delivery Virtual 2021, May 4th - 7th, 2021
Respiratory Drug Delivery 2021 (RDD 2021), one of the top-class conferences about pulmonary and nasal drug delivery, will be held for the second year in a virtual format, as the global pandemic situation keeps on obliging us to stay physically apart. As such, Qualicaps® is proud to announce its participation at this virtual edition as an exhibit sponsor, where experts will address contemporary topics alongside poster presentations, workshops, and on-screen knowledge spaces in a setting designed to maximize networking.
After April 27, recorded speaker, workshop and poster presentations may be viewed 24/7 as often as you please until June 30, 2021.
Click here to get to know further about this must-attend virtual event:https://www.rddonline.com/rdd/rdd.php?id=20&sid=1
Qualicaps® Europe, S.A.U. expands its presence in South Asia region
At the core of its strategy, management style, and its enterprise-wide responsibility, Qualicaps® continues to endorse its KAITEKI value management system and corporate culture by promoting the betterment of individuals, society and Earth. Besides extending its geographical reach to Middle East and Africa last year, Qualicaps® Europe S.A.U has recently expanded its presence into the South Asia region also.
With two production sites based in Europe, and teams comprised of capsule manufacturing experts located in the EMEA & South Asia regions, Qualicaps® is highly prepared to continue offering, in these three newly integrated regions, high standards of quality, functionality, and performance: product and service quality, collaboration in the scientific, technical and service aspects of the capsule delivery form, and flexibility to fulfill special customer needs.
As such, over the past years, by doubling down on its commitment to domestic and overseas’ customers, Qualicaps® Europe S.A.U has substantially invested in expanding its production capacity and capabilities in their integrated European sites in Madrid, Spain and Bucharest, Romania. Thanks to these efforts, Qualicaps® Europe S.A.U is able to ensure the continuity of supply to multi-national customers, as well as local and regional ones. Altogether they have enabled the company to increase its overall market presence, while continuing to operate in full as it has been performing for the past year. Thus, maintaining its lead-time for non-forecasted orders between 6 to 8 weeks.
Qualicaps® Europe, S.A.U. expands its presence in Middle East and Africa
In line with Qualicaps‘ mission to contribute to health and well-being on a worldwide scale, Qualicaps® Europe has expanded its presence in Middle East & Africa after signing Agency & Distribution partnership agreements with a number of market leading companies in the region. Those partnerships strengthen the presence of Qualicaps® in MEA and allow it to expand its world class service and product offerings by providing local support to some of the world’s fast-growing pharmaceutical markets, including Egypt, Saudi Arabia, UAE to name a few.
As part of the global industrial and healthcare group Mitsubishi Chemical Holdings Corporation (MCHC), Qualicaps® Europe over the past years has substantially invested in expanding its production capacity and capabilities in their integrated European sites in Madrid, Spain and Bucharest, Romania. As a result, Qualicaps® Europe has now additional flexibility for both planned production orders as well as warehouse-available products, with shortened lead times and a competitive cost basis.
Qualicaps Europe, S.A.U. receives cofunding awarded by the European Union through the Centre for the Development of Industrial Technology (CDTI) and the European Fund of Regional Development (FEDER - Fondo Europeo de Desarrollo Regional).
In response to the growing interest of the market in the commercialization of nutritional supplements that require the partial release of the nutrients along the gut in order to reach their maximum efficacy, Qualicaps® has developed a new slow-release capsule for the administration of these products.. The novel capsule, Nutra’V Slow, is specifically designed to target moisture-sensitive and acid-labile ingredients by slowing down capsule rupture and release of contents. The elaboration process of Nutra’V Slow was designed to integrate seamlessly with the production processes of a company’s nutritional supplements.
An R&D project pursuing the elaboration of the novel slow-release cellulose capsule, together with the definition of a robust and reliable new ad-hoc experimental production process was addressed. The objectives taken into consideration were the following:
• Design of a formulation based on cellulose so that the slow-release properties can be fulfilled.
• Development of the stages of the experimental production process specifically designed for the novel slow-release capsule.
• Development of all elements required for the implementation of the process.
• Formal specification of the novel process.
The specific project, valued at over 400 thousands euros, has been conducted during the last year by Qualicaps Europe, S.A.U., located in Alcobendas (Madrid) and has been awarded cofunding by the European Union through the Centre for the Development of Industrial Technology (CDTI) and the European Regional Development Fund (FEDER - Fondo Europeo de Desarrollo Regional).
CPhI Worldwide 2019, 5-7 November 2019
CPhI Worldwide is the world's largest pharmaceutical exhibition, where six zones representing each stage of the pharmaceutical supply chain are reunited under the same roof, this year in Frankfurt.
We would be delighted to welcome you to our booth (80K70– Integrated Pharma) and introduce you to the Qualicaps® team, as well as to our product and service offering for the hard-capsule dosage form throughout the drug product life cycle.
Come and visit us at booth No. 80K70 to learn more about our capsule customization capabilities.
Supply Side West, October 17-18, 2019
SupplySide West is the largest gathering of health & nutrition professionals bringing together more than 17,000 ingredient buyers and suppliers from throughout the industry. Make plans to speak to one of our capsule representatives about how our capsules are the perfect complement to your health and nutrition brand. Also, see Qualicaps®’ LIS-Labo, Laser Imprinting Machine and Technophar’s NEW SGM612NEXTGen soft capsule machine firsthand at the show.
Get to know the Qualicaps® team at SupplySide West in Las Vegas at Booth 1865.
AAPS PharmSci 360, November 3-6, 2019
Qualicaps® is proud to attend AAPS PharmSci 360, this year in beautiful San Antonio, Texas. The event attracts pharmaceutical professionals in all stages of drug development. We would be delighted to have you visit our booth and get to know the Qualicaps® team, as well as our products and services for the hard capsule dosage form.
Also, join us for our partner presentation “Considerations for Drug Product Development Using Two-Piece Hard Capsules” on November 5 at 10:30 a.m. in Partner Presentation Classroom 1, Exhibit Hall 234. We will compare capsule types available to assist in choosing a drug delivery form based off their APIs. Additional focus will be given to unique formulations such as moisture sensitive, dry powders, and liquids.
Get to know the Qualicaps® team at PharmSci 360 in San Antonio, Texas at Booth 1502.
USING HARD CAPSULES FOR MOISTURE SENSITIVE AND HYGROSCOPIC APIs
Join us on Tuesday, October 15, 2019 at 12:30 PM EST for a webinar that clears up common misconceptions about the use of the hard capsules with moisture sensitive and hygroscopic APIs.
For years, the common conception was the hard two-piece capsules are not well-suited to these types of APIs. However, new capsules with very low moisture contents are now available for use with very moisture-sensitive compounds and are designed for use with solid oral dose and/or dry powder inhalation.
We will address the causes of API instability, what impacts stability, and possible improvements with the proper hard capsule choice. The information is intended to help in the process of making drug delivery choices.
Click here to register today: https://www.pathlms.com/aaps/webinars/5945
CPhI Middle East & Africa, September 16–18, 2019
For the second time, the CPhI Middle East & Africa event is meant to become the region's most comprehensive pharmaceutical platform. Together, with its co-located events iCSE, P-MEC, InnoPack and FDF, where over 4,900 key visiting pharma suppliers and buyers, along with a wide range of exhibitor from all across the entire pharma supply chain will meet and network under one roof. We would be pleased to welcome you in our booth G80 to introduce you our product and service offering for the hard capsule dosage form throughout the drug product life cycle.